Provided by Tiger Fintech (Singapore) Pte. Ltd.

INCANNEX HEALTHCARE LTD

0.5810
-0.0441-7.05%
Post-market: 0.5800-0.0010-0.17%19:30 EDT
Volume:14.98K
Turnover:9.05K
Market Cap:16.00M
PE:-0.42
High:0.6300
Open:0.5900
Low:0.5800
Close:0.6251
Loading ...

Psychedelic: Clearmind completes clinical site initiations for AUD trial

TipRanks
·
Yesterday

Incannex completes Phase 2 patient enrollment for RePOSA study of IHL-42X

TIPRANKS
·
03 Apr

BRIEF-Incannex Healthcare Completes Phase 2 Enrollment In Reposa Phase 2/3 Trial Of Ihl-42X, An Oral Once-Daily Treatment For Obstructive Sleep Apnea (Osa)

Reuters
·
03 Apr

Incannex Healthcare Completes Phase 2 Enrollment in Reposa Phase 2/3 Trial of Ihl-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (Osa)

THOMSON REUTERS
·
03 Apr

Incannex Healthcare Files Registration Statement for Sale of Shares

MT Newswires Live
·
25 Mar

Psychedelic: Exclusive talk with biotech company Clearmind Medicine

TipRanks
·
22 Mar

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

TipRanks
·
14 Mar

Incannex Healthcare Prices $12.5 Million Private Stock Offering

MT Newswires Live
·
08 Mar

BRIEF-Incannex Healthcare Inc. Announces Pricing Of $12.5 Million Private Placement Priced At The Market Under Nasdaq Rules

Reuters
·
08 Mar

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

THOMSON REUTERS
·
08 Mar

Press Release: Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

Dow Jones
·
08 Mar

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

Newsfile
·
19 Feb

BRIEF-Incannex Healthcare Reports Fiscal Second Quarter Results

Reuters
·
14 Feb

Incannex Healthcare Inc Qtrly Loss per Share $0.33

THOMSON REUTERS
·
14 Feb

Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Dow Jones
·
14 Feb

Incannex Healthcare Appoints Alison Wimms, Ph.d. to Newly Formed Ihl-42X Obstructive Sleep Apnea (Osa) Clinical Advisory Board

THOMSON REUTERS
·
04 Feb

Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

GlobeNewswire
·
04 Feb

Incannex announces results from PK study of IHL-42X

TIPRANKS
·
23 Jan

Incannex Healthcare Inc - No Serious Adverse Events Reported in Ihl-42X Study

THOMSON REUTERS
·
23 Jan

Incannex Healthcare Announces Positive Topline Results From Pharmacokinetics (Pk) Study of Ihl-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea

THOMSON REUTERS
·
23 Jan